In addition, three distinct clinical trials are investigating the efficacy between Elotuzumab and Nivolumab [an anti-Programmed Death-1 (PD-1) mAb] in r/r MM patients [NCT02726581 (CheckMate-602, phase III)], (NCT02612779, phase II), and (NCT03227432, phase II) (ClinicalTrials.gov) (Table 1). Here, PDCD1 is linked to Miyoshi myopathy.